Literature DB >> 19450319

Pelvic inflammatory disease.

Jonathan D C Ross1.   

Abstract

INTRODUCTION: Pelvic inflammatory disease is caused by infection of the upper female genital tract and is often asymptomatic. Pelvic inflammatory disease is the most common gynaecological reason for admission to hospital in the USA and is diagnosed in almost 2% of women aged 16-45 years consulting their GP in England and Wales. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of empirical treatment compared with treatment delayed until the results of microbiological investigations are known? How do different antimicrobial regimens compare? What are the effects of routine antibiotic prophylaxis to prevent pelvic inflammatory disease before intrauterine contraceptive device (IUD)8 insertion? We searched: Medline, Embase, The Cochrane Library and other important databases up to May 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 9 systematic reviews, RCTs or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics (oral, parenteral, empirical treatment, treatment guided by test results, different durations, outpatient, inpatient), and routine antibiotic prophylaxis (before intrauterine device insertion in women at high risk or low risk).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19450319      PMCID: PMC2907941     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  50 in total

Review 1.  Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases.

Authors:  C K Walker; K A Workowski; A E Washington; D Soper; R L Sweet
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

Review 2.  Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review.

Authors:  Anshu P Mohllajee; Kathryn M Curtis; Herbert B Peterson
Journal:  Contraception       Date:  2005-10-19       Impact factor: 3.375

Review 3.  Is Mycoplasma genitalium a cause of pelvic inflammatory disease?

Authors:  Jonathan D C Ross
Journal:  Infect Dis Clin North Am       Date:  2005-06       Impact factor: 5.982

4.  Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial.

Authors:  J D C Ross; H S Cronjé; T Paszkowski; I Rakoczi; D Vildaite; A Kureishi; M Alefelder; P Arvis; P Reimnitz
Journal:  Sex Transm Infect       Date:  2006-05-24       Impact factor: 3.519

5.  [The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections].

Authors:  N Ciraru-Vigneron; G Bercau; E Sauvanet; R Nguyen Tan Lung; A Felten; J B Leaute; T Zylbertrest; J Barrier
Journal:  Pathol Biol (Paris)       Date:  1986-06

6.  Effectiveness of treatment strategies of some women with pelvic inflammatory disease: a randomized trial.

Authors:  Roberta B Ness; Gail Trautmann; Holly E Richter; Hugh Randall; Jeffrey F Peipert; Deborah B Nelson; Diane Schubeck; S Gene McNeeley; Wayne Trout; Debra C Bass; David E Soper
Journal:  Obstet Gynecol       Date:  2005-09       Impact factor: 7.661

7.  Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial.

Authors:  Roberta B Ness; David E Soper; Robert L Holley; Jeffrey Peipert; Hugh Randall; Richard L Sweet; Steven J Sondheimer; Susan L Hendrix; Antonio Amortegui; Giuliana Trucco; Thomas Songer; Judith R Lave; Sharon L Hillier; Debra C Bass; Sheryl F Kelsey
Journal:  Am J Obstet Gynecol       Date:  2002-05       Impact factor: 8.661

8.  Trends in pelvic inflammatory disease hospital discharges and ambulatory visits, United States, 1985-2001.

Authors:  Madeline Y Sutton; Maya Sternberg; Akbar Zaidi; Michael E St Louis; Lauri E Markowitz
Journal:  Sex Transm Dis       Date:  2005-12       Impact factor: 2.830

9.  Comparison of three regimens recommended by the Centers for Disease Control and Prevention for the treatment of women hospitalized with acute pelvic inflammatory disease.

Authors:  D L Hemsell; B B Little; S Faro; R L Sweet; W J Ledger; A S Berkeley; D A Eschenbach; P Wölner-Hanssen; J G Pastorek
Journal:  Clin Infect Dis       Date:  1994-10       Impact factor: 9.079

10.  Overall clinical experience with aztreonam in the treatment of obstetric-gynecologic infections.

Authors:  S A Henry
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec
View more
  1 in total

Review 1.  How the Cervical Microbiota Contributes to Cervical Cancer Risk in Sub-Saharan Africa.

Authors:  Cameron Klein; Crispin Kahesa; Julius Mwaiselage; John T West; Charles Wood; Peter C Angeletti
Journal:  Front Cell Infect Microbiol       Date:  2020-02-12       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.